Generalizability vs. Transportability in Trials

evidenceinthewild:

If practitioners can’t articulate why they are randomizing when there is no comparison, that itself reflects exactly the misunderstanding of Fisher’s framework you’re describing, and may even strengthen rather than soften your point.

Correct. See also related presentation here to the International Society for Biopharmaceutical Statistics (ISBS) with practical examples how understanding Fisher’s inferential machinery can lead to practice-changing RCTs. Connection with information theory here (more extended discussion here). We have also shown here that the quasirandomness fallacy occurs in more than half of oncology phase 3 RCTs and it is increasing over time. Concurrently, the incidence of RNCTs is also increasing.